###begin article-title 0
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
Polymorphism in the MHC2TA Gene Is Associated with Features of the Metabolic Syndrome and Cardiovascular Mortality
###end article-title 0
###begin p 1
Conceived and designed the experiments: OM MO. Performed the experiments: MO. Analyzed the data: PA EL. Contributed reagents/materials/analysis tools: LG GB OM CA MO. Wrote the paper: LG GB EL OM CA MO.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Recently, a -168A-->G polymorphism in the MHC class II transactivator gene (MHC2TA) was shown to be associated with increased susceptibility to myocardial infarction (MI).
###end p 3
###begin title 4
Aim
###end title 4
###begin p 5
To confirm the association between the MHC2TA -168A-->G polymorphism and MI and to study its putative role for microalbuminuria, the metabolic syndrome (MetS) and cardiovascular mortality.
###end p 5
###begin title 6
Materials and Methods
###end title 6
###begin p 7
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
Using an allelic discrimination method we genotyped 11,064 individuals from three study populations: 1) 4,432 individuals from the Botnia type 2 diabetes (T2D) study, 2) 1,222 patients with MI and 2,345 control subjects participating in the Malmo Diet and Cancer study and comprising an MI case-control sample, and 3) 3,065 T2D patients from the Local Swedish Diabetes registry.
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
No association between the -168A-->G polymorphism in MHC2TA and MI was observed. However, in the Botnia cohort the AG/GG genotypes were associated with cardiovascular mortality after MI (1.78 [1.09-2.92], p = 0.02). In addition, the AG/GG genotypes were more common in subjects with MetS (40.1% vs. 36.9%, p = 0.03) and in non-diabetic subjects with microalbuminuria (45.4% vs. 36.5%, p = 0.003) compared to control subjects.
###end p 9
###begin title 10
Conclusions
###end title 10
###begin p 11
A polymorphism in MHC2TA was associated with cardiovascular mortality and predictors of cardiovascular mortality, microalbuminuria and MetS.
###end p 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 347 350 347 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Wang1">[1]</xref>
###xml 456 459 456 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Greenland1">[2]</xref>
###xml 461 464 461 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Khot1">[3]</xref>
###xml 568 571 568 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Colditz1">[4]</xref>
###xml 572 575 572 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Topol1">[7]</xref>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
Cardiovascular disease is the leading cause of death in Sweden and in most Western countries. Almost 50% of deceased individuals died due to cardiovascular causes in Sweden 2005 (Swedish National Board of Health and Welfare ). Both genetic and environmental factors modify the risk for cardiovascular diseases including myocardial infarction (MI) [1],smoking, dyslipidaemia, diabetes, obesity and hypertension, are present in up to 90% of patients with MI [2], [3]. Family history of MI has been shown to be a strong independent risk factor for coronary heart disease [4]-[7].
###end p 13
###begin p 14
###xml 107 110 107 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Mogensen1">[8]</xref>
###xml 137 140 137 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Yudkin1">[9]</xref>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Lee1">[10]</xref>
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Libby1">[11]</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Festa1">[12]</xref>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
Microalbuminuria is an established risk marker for cardiovascular morbidity and mortality both in diabetic [8] and non-diabetic patients [9]. Inflammation is believed to play a major role in the pathogenesis of both microalbuminuria [10] and MI [11]. Insulin resistance has been proposed as a common denominator for these conditions, and has also been related to subclinical chronic inflammation [12].
###end p 14
###begin p 15
###xml 67 73 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 164 168 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
###xml 238 244 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 485 491 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 588 592 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
###xml 302 308 <span type="species:ncbi:9606">humans</span>
###xml 378 381 <span type="species:ncbi:10116">rat</span>
A -168 A-->G polymorphism in the MHC class II transactivator gene (MHC2TA) was recently found to be associated with MI, rheumatoid arthritis and multiple sclerosis [13]. The -168 A-->G polymorphism was associated with lower expression of MHC2TA after stimulation of leukocytes with interferon-gamma in humans and differences in expression of MHC class II molecules in different rat strains. Because of the role of MHC class II molecules in recognition of antigen molecules, genes like MHC2TA that can influence expression of MHC class II, are also candidate genes for autoimmune diseases [13].
###end p 15
###begin p 16
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
To address this issue, we searched for any association between MHC2TA -168 A-->G polymorphism and cardiovascular morbidity and mortality as well as their predictors, microalbuminuria and the metabolic syndrome (MetS).
###end p 16
###begin title 17
Materials and Methods
###end title 17
###begin title 18
Study Subjects
###end title 18
###begin p 19
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients were selected from three large populations in Finland and Sweden; the Botnia study, the Malmo Diet and Cancer Study (MDC) and the Diabetes Registry in Southern Sweden (DR). The protocols were approved by local Ethics committees, and informed consent was obtained from all subjects.
###end p 19
###begin title 20
The Botnia Study
###end title 20
###begin p 21
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Isomaa1">[14]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Groop1">[15]</xref>
The Botnia Study was initiated in 1990 and represents a large population-based type 2 diabetes (T2D) family study in Finland and Sweden, aiming at identification of genes increasing susceptibility to T2D, MetS and associated complications. Details of the study cohort, sampling strategy as well as anthropometric and metabolic measurements have been described earlier [14], [15]. At the baseline examination, a structured questionnaire was completed by specially trained nurses, covering information about diseases other than T2D (particularly hypertension, coronary heart disease, MI and stroke) and data on smoking habits. Both previous and current smokers were recorded as smokers. Diagnosis of MI was always established in the hospital. Microalbuminuria was defined as urinary albumin excretion rate >20 microg/min in an overnight urine collection.
###end p 21
###begin p 22
###xml 883 887 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Pasternak1">[16]</xref>
Total and cardiovascular mortality were assessed with a median follow up time of 7.9 years and the mortality data was obtained from the central death-certificate registry in Finland. Cardiovascular mortality was classified using the 9th revision of the International Classification of Diseases (cardiovascular diagnosis codes 390-459) before 1997 and the 10th revision (codes 100-199) thereafter. Causes of death were classified as 1) cardiovascular death (coronary heart disease), cerebrovascular disease (including both thrombotic stroke and cerebral haemorrhage) or other cardiovascular (including pulmonary embolism, abdominal aortic aneurysm, hypertensive complications, general atherosclerosis and peripheral artery disease with gangrene) or 2) other causes of death (neoplasm, violent or other). MetS was defined according to the National Cholesterol Education Program (NCEP) [16].
###end p 22
###begin p 23
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
In total, 4,432 individuals were genotyped for the MHC2TA -168 A-->G polymorphism including 2,864 individuals without diabetes mellitus and 1,557 with T2D. Data on MI was available in 97% and on microalbuminuria in 64% of the subjects. Data on cardiovascular mortality was available for all patients.
###end p 23
###begin title 24
The MI case- control population from the Malmo diet and cancer study (MDC)
###end title 24
###begin p 25
###xml 49 53 49 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Berglund1">[17]</xref>
###xml 396 398 396 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">st</sup>
###xml 88 91 <span type="species:ncbi:9606">men</span>
###xml 113 118 <span type="species:ncbi:9606">women</span>
###xml 506 513 <span type="species:ncbi:9606">Patient</span>
###xml 603 610 <span type="species:ncbi:9606">Patient</span>
###xml 711 718 <span type="species:ncbi:9606">Patient</span>
The Malmo Diet and Cancer study population (MDC) [17] includes 28,098 randomly selected men (born 1923-1945) and women (born 1923-1950) living in the city of Malmo (population 250,000) in Sweden. A baseline examination was carried out between 1991 and 1996 encompassing a comprehensive assessment of lifestyle factors, heredity, medication as well as previous and current diseases. On December 31st, 2000 the study population was checked against the Swedish National Board of Health and Welfare's National Patient Registry and Cause of Death Registry. MI cases (first MI) were identified in the Swedish Patient Registry or in the Swedish Cause of Death Registry; using ICD 9-10 codes 410 and I21 in the Swedish Patient Registry and 410-414 and I21-I25 in the Swedish Cause of Death Registry.
###end p 25
###begin p 26
###xml 284 290 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 94 101 <span type="species:ncbi:9606">patient</span>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
Two age- (+/-1 year) and gender-matched controls without MI from MDC were assigned to each MI patient, resulting in a case-control material consisting of 1,244 MI patients and 2,488 controls. Of total 3,732 individuals, 3,657 were successfully genotyped for the A-->G polymorphism in MHC2TA. Diabetes diagnosis was defined as self reported earlier diagnosis, fasting blood glucose >/= 6.1 mmol/l and/or treatment for earlier diagnosed diabetes mellitus.
###end p 26
###begin title 27
Diabetes registry in Southern Sweden (DR)
###end title 27
###begin p 28
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Lindholm1">[18]</xref>
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 266 273 <span type="species:ncbi:9606">patient</span>
3,065 T2D patients from a local diabetes registry in Southern Sweden [18], most of them enrolled at the Department of Endocrinology, University Hospital MAS, Malmo, were selected and genotyped for the MHC2TA -168 A-->G polymorphism. Data on MI was obtained from the patient records and was available in 77% and on microalbuminuria in 70% of the subjects.
###end p 28
###begin title 29
Analytical techniques
###end title 29
###begin p 30
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1c</sub>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Groop1">[15]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Lindholm1">[18]</xref>
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-vonWowern1">[19]</xref>
HbA1c, total cholesterol, HDL-cholesterol, triglycerides and P-creatinine were measured with standard laboratory methods. A detailed description of the methods are found elsewhere [15], [18], [19]. The urinary albumin concentration was in DR determined first by immunonephelometric method (Beckman Instruments, CA, USA) until 1998, and thereafter by an immunoturbimetric method (Beckman Coulter, Beckman Instruments, CA, USA). In the Botnia study, urine albumin concentration was determined with a radioimmunoassay with a detection limit of 2 mg/l. Microalbuminuria was defined as AER of >/=20 microg/min.
###end p 30
###begin title 31
Genotyping
###end title 31
###begin p 32
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
In total 11,064 individuals were successfully genotyped for the -168 A/G polymorphism (rs3087456) using allelic discrimination method on the ABI 7900 instrument (Applied Biosystems, Foster City, CA). Risk genotypes were defined according to earlier published report [13]. The genotyping success rate was 97.9, 98.0 and 99.0% in Botnia, MDC and DR cohorts, respectively.
###end p 32
###begin title 33
Statistical methods
###end title 33
###begin p 34
###xml 50 52 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 55 57 53 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 664 670 662 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
Data are presented as mean +/- SD or as median [25th-75th] percentile. Chi-square tests were used to analyze differences between allele- and genotype frequencies. To test differences between group means, the Student's two-tailed t-test was used for normally distributed values and Mann-Whitney U-test for non-normally distributed medians. In order to identify factors associated with MI and microalbuminuria, a multiple logistic regression analysis with forward selection was performed. Because of the nature of Botnia cohort as a family collection, the analyses were adjusted for the family relations. For the mortality analyses, clinical variables together with MHC2TA genotypes were entered into a forward stepwise Cox regression model adjusted for sex, age and family relations.
###end p 34
###begin p 35
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Purcell1">[20]</xref>
All data were analyzed with a NCSS 2004 (NCSS statistical software, Kaysville, UT, USA). A p-value of <0.05 was considered statistically significant. Power analysis was made using Genetic Power Calculator [20].
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 62 69 62 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000064-t001">Table 1</xref>
###xml 114 120 114 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 230 237 230 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000064-t002">Table 2</xref>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
The clinical characteristics of the study groups are given in Table 1. The genotype and allele frequencies of the MHC2TA polymorphism were similar in patients with or without MI, regardless of the study population and T2D status (Table 2). No association with T2D was observed, neither in the Finnish (Botnia), nor in the Swedish (MDC or DR) cohorts.
###end p 37
###begin p 38
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 158 165 158 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000064-t003">Table 3</xref>
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 350 356 350 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 501 508 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000064-t003">Table 3</xref>
###xml 510 518 510 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000064-g001">Figure 1</xref>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 728 736 <span type="species:ncbi:9606">patients</span>
No correlation between the MHC2TA -168 AG/GG genotypes and cardiovascular mortality was found in the Botnia Study population (HR 0.96 [0.75-1.22], p = 0.74) (Table 3). As the MHC2TA polymorphism was earlier shown to be associated with MI, we performed a subgroup analysis of individuals with previous history of MI. In fact, among these patients the MHC2TA AG/GG genotypes were associated with increased risk of cardiovascular death compared with AA genotype carriers (HR 1.76 [1.09-2.82], p = 0.02) (Table 3, Figure 1). We also tested the MHC2TA GG genotype against the AA or AG genotypes and found that the GG genotype was protective against cardiovascular death in the whole group (HR 0.38 [0.16-0.92], p = 0.03), but not in patients with previous MI (HR 0.45 [0.49-4.16], p = 0.48).
###end p 38
###begin p 39
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 221 228 221 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000064-t002">Table 2</xref>
###xml 368 375 368 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000064-t002">Table 2</xref>
###xml 528 534 528 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 721 729 <span type="species:ncbi:9606">patients</span>
The MHC2TA AG/GG genotypes were more frequently found among patients with MetS (40.1 vs. 36.9%, p = 0.030) as well as among non-diabetic individuals with microalbuminuria in the Botnia cohort (50.0% vs. 36.0%, p = 0.003, Table 2). In contrast, the AG/GG genotypes were not associated with microalbuminuria among T2D patients, neither in the Botnia, nor the DR cohort (Table 2). Correspondingly, logistic regression analysis with age, waist-hip ratio, fasting insulin, systolic- and diastolic blood pressure, smoking, gender and MHC2TA AG/GG genotypes as independent factors, revealed the AG/GG genotypes as risk factors for microalbuminuria in non-diabetic subjects (OR 2.07 [1.35-3.18], p = 0.0009), but not in diabetic patients (OR 1.22 [0.80-1.84], p = 0.35).
###end p 39
###begin p 40
###xml 209 217 <span type="species:ncbi:9606">patients</span>
The statistical power to detect differences in risk of MI according to genotype assuming dominant model and genotype relative risk of 1.2 was 32.0% in Botnia, 95.1% in the MDC cohort and 36.5% for Swedish T2D patients (from DR). The corresponding figures when assuming genotype relative risk of 1.5 were 95.0, 100.0, and 92.7%. In the pooled Swedish sample the power was 97.0% assuming a relative risk of 1.2 and 100% at the level of 1.5.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 68 74 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 281 285 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
###xml 329 333 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
###xml 608 613 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
The key finding of the present study was an association between the MHC2TA -168 A-->G polymorphism and cardiovascular mortality as well as with predictors thereof, microalbuminuria and MetS. These findings support the earlier report of association between this polymorphism and MI [13]. However, in contrast to the earlier study [13], the -168 A-->G was not associated with MI in our study. One possible explanation could be differences in definition of MI. Our study consisted of population based material, where the information of MI was collected retrospectively, whereas the study population of Swanberg et al. was recruited from all patients below 60 yrs. that were admitted to the hospital for acute MI.
###end p 42
###begin p 43
###xml 61 64 61 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Yudkin1">[9]</xref>
###xml 142 146 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Aso1">[21]</xref>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Mogensen2">[22]</xref>
###xml 890 896 890 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 663 671 <span type="species:ncbi:9606">patients</span>
Microalbuminuria is a risk marker for cardiovascular disease [9] and has been suggested to reflect a state of low-grade systemic inflammation [21]. Several factors like high blood pressure, hyperglycaemia, smoking, heart failure and renal atherosclerosis, all of which themselves are associated with increased inflammatory activity, are known to play a role in the development of microalbuminuria [22]. The association with microalbuminuria was, however, restricted to non-diabetic subjects. This could reflect the fact that in diabetic subjects other factors including hyperglycaemia may influence the day-to-day variation in albumin excretion. The non-diabetic patients with microalbuminuria had several features of MetS including higher waist to hip ratio, higher HOMA -index, and higher blood pressure (data not shown) compared to individuals without microalbuminuria. Accordingly, the MHC2TA -168A-->G polymorphism was also associated with MetS.
###end p 43
###begin p 44
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 254 261 252 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0000064-t003">Table 3</xref>
###xml 266 274 264 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000064-g001">Figure 1</xref>
###xml 358 362 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Libby1">[11]</xref>
###xml 572 576 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-vanderWal1">[23]</xref>
###xml 763 769 761 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 928 932 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
###xml 1126 1130 1124 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
###xml 1337 1341 1335 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000064-Swanberg1">[13]</xref>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
Thus, the MHC2TA -168 A-->G polymorphism influenced both outcome and prediction of cardiovascular disease. Among patients with previous MI, carriers of the AG or GG genotypes had increased risk of cardiovascular death compared with AA genotype carriers (Table 3 and Figure 1). It is known that inflammation plays a key role in development of atherosclerosis [11] and activated T-lymphocytes are already present in the atherosclerotic plaque, as well as in the immediate site of plaque rupture or superficial erosions in patients who have died due to MI or unstable angina [23]. Our results suggest that the G-allele (and in particular the AG genotype) could be a risk factor for cardiovascular mortality after MI, although the mechanism remains unclear. Swanberg et al. suggested that the G allele could cause reduced induction of MHC class II genes thus leading to less efficient presentation of antigens to regulatory T cells [13]. However, the previous association analysis compared AG and GG genotype carriers to AA genotype carriers and showed that in particular the AG (and not GG) genotype carriers were at higher risk [13]. In contrast, the expression analysis compared a pool of AA and AG genotype carriers to GG genotype carriers thus not challenging the possibility of a difference between the more common AA and AG genotypes [13]. Interestingly, we observed that in fact the GG carriers had a lower risk for death due to cardiovascular events compared to AA or AG genotype carriers (HR 0.38 [0.16-0.92]). It is therefore unclear whether the risk really is associated with less induction of the MHC II genes in response to inflammation stimuli. To clarify this issue, expression levels of all genotypes would therefore be of interest, especially comparison between the AA and AG genotypes.
###end p 44
###begin p 45
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
Taken together, despite lack of a relationship between MHC2TA and MI in this large association study, we show that the AG/GG genotypes of the MHC2TA -168 A-->G polymorphism are associated with microalbuminuria and features of MetS. This, in turn, translates into an increased risk of cardiovascular mortality.
###end p 45
###begin title 46
References
###end title 46
###begin article-title 47
Molecular genetics of coronary artery disease.
###end article-title 47
###begin article-title 48
Major risk factors as antecedents of fatal and nonfatal coronary heart disease events.
###end article-title 48
###begin article-title 49
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Prevalence of conventional risk factors in patients with coronary heart disease.
###end article-title 49
###begin article-title 50
###xml 95 100 <span type="species:ncbi:9606">women</span>
A prospective study of parental history of myocardial infarction and coronary heart disease in women.
###end article-title 50
###begin article-title 51
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction.
###end article-title 51
###begin article-title 52
Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro.
###end article-title 52
###begin article-title 53
Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction.
###end article-title 53
###begin article-title 54
Microalbuminuria: an early marker of renal involvement in diabetes.
###end article-title 54
###begin article-title 55
Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.
###end article-title 55
###begin article-title 56
Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation.
###end article-title 56
###begin article-title 57
Pathophysiology of coronary artery disease.
###end article-title 57
###begin article-title 58
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).
###end article-title 58
###begin article-title 59
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction.
###end article-title 59
###begin article-title 60
Cardiovascular morbidity and mortality associated with the metabolic syndrome.
###end article-title 60
###begin article-title 61
Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects.
###end article-title 61
###begin article-title 62
Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults.
###end article-title 62
###begin article-title 63
The Malmo Diet and Cancer Study. Design and feasibility.
###end article-title 63
###begin article-title 64
Classifying diabetes according to the new WHO clinical stages.
###end article-title 64
###begin article-title 65
Genetic variance of SGK-1 is associated with blood pressure, blood pressure change over time and strength of the insulin-diastolic blood pressure relationship.
###end article-title 65
###begin article-title 66
Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.
###end article-title 66
###begin article-title 67
Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia.
###end article-title 67
###begin article-title 68
Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion.
###end article-title 68
###begin article-title 69
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.
###end article-title 69
###begin title 70
Figures and Tables
###end title 70
###begin p 71
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Cardiovascular mortality in the Botnia cohort in patients with previous MI according to MHC2TA -168 A-->G genotypes.
###end p 71
###begin p 72
Kaplan Meier survival curves illustrating a higher risk for CV mortality (HR 1.76 [1.09-2.82], p = 0.02) in AG/GG genotype carriers with previous history of MI.
###end p 72
###begin title 73
Clinical characteristics of the study subjects.
###end title 73
###begin p 74
###xml 128 136 <span type="species:ncbi:9606">patients</span>
Numbers are mean+/-SD or percent. *Both previous and current smoking. P-values refer to comparison between non-diabetic and T2D patients.
###end p 74
###begin title 75
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC2TA</italic>
The genotype frequencies of the MHC2TA -168 A-->G polymorphism in different study populations according to history of previous MI and microalbuminuria status.
###end title 75
###begin p 76
###xml 53 61 <span type="species:ncbi:9606">patients</span>
The numbers are allele frequencies (%) and number of patients. P-values refer to comparison between genotype frequencies of the -168A-->Tau risk genotypes (AG or GG) among individuals with or without MI and with or without microalbuminuria, respectively.
###end p 76
###begin title 77
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Predictors of cardiovascular mortality among all individuals and patients with previous MI from the Botnia study.
###end title 77
###begin p 78
Numbers are hazard ratio (HR) and 95% Confidence limits. HRs were mutually adjusted.
###end p 78
###begin p 79
HR per mmHg
###end p 79
###begin p 80
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Professor Leif Groop has been a member of the Advisory Board of the Bristol-Myers Squibb BMS.
###end p 80
###begin p 81
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the Diabetes Program at Lund University (DPLU), the Foundation for Strategic Research through the National Network for Cardiovascular Research, the Swedish Medical Research Council, the Albert Pahlssons Foundation, the Malmo University Hospital Foundations, the Crafoord Foundation, the Novo Nordisk Foundation, the Swedish Heart and Lung Foundation, the Medical Faculty of Lund University and the Skane County Council Research and Development Foundation. The Botnia Study is principally supported by the Sigrid Juselius Foundation, the Academy of Finland, the Finnish Diabetes Research Foundation, the Folkhalsan Research Foundation, and the Viktor Ollqvist Foundation.
###end p 81

